Latest Insider Transactions at Kal Vista Pharmaceuticals, Inc. (KALV)
This section provides a real-time view of insider transactions for Kal Vista Pharmaceuticals, Inc. (KALV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of KalVista Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of KalVista Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 18
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,020
-23.56%
|
$80,200
$10.73 P/Share
|
|
Aug 17
2023
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,582
+17.2%
|
-
|
|
Aug 17
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,195
+21.8%
|
-
|
|
Aug 17
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,494
+19.06%
|
-
|
|
Aug 17
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,494
+12.81%
|
-
|
|
Aug 17
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,529
+35.25%
|
-
|
|
May 18
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,604
-6.52%
|
$26,040
$10.14 P/Share
|
|
May 18
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,780
-17.6%
|
$27,800
$10.14 P/Share
|
|
May 18
2023
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
5,627
-4.21%
|
$56,270
$10.14 P/Share
|
|
May 18
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,786
-2.61%
|
$17,860
$10.14 P/Share
|
|
May 18
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,037
-4.91%
|
$40,370
$10.14 P/Share
|
|
May 17
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,205
+9.53%
|
-
|
|
May 17
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,447
+28.99%
|
-
|
|
May 17
2023
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,750
+8.71%
|
-
|
|
May 17
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,205
+5.78%
|
-
|
|
May 17
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,364
+10.23%
|
-
|
|
Feb 17
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,954
-6.37%
|
$34,678
$7.66 P/Share
|
|
Feb 17
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,363
+10.75%
|
-
|
|
Feb 17
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,727
-7.09%
|
$19,089
$7.66 P/Share
|
|
Feb 17
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,204
+9.86%
|
-
|
|
Feb 17
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,228
-3.35%
|
$15,596
$7.66 P/Share
|
|
Feb 17
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,204
+5.94%
|
-
|
|
Feb 17
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,412
-26.74%
|
$23,884
$7.66 P/Share
|
|
Feb 17
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,446
+50.52%
|
-
|
|
Feb 17
2023
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
6,700
-5.25%
|
$46,900
$7.66 P/Share
|
|
Feb 17
2023
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,749
+9.08%
|
-
|
|
Nov 18
2022
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
722
-10.83%
|
$3,610
$5.44 P/Share
|
|
Nov 18
2022
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
1,785
-1.53%
|
$8,925
$5.44 P/Share
|
|
Nov 18
2022
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
530
-0.84%
|
$2,650
$5.44 P/Share
|
|
Nov 18
2022
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
722
-1.04%
|
$3,610
$5.44 P/Share
|
|
Nov 18
2022
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,139
-3.22%
|
$5,695
$5.44 P/Share
|
|
Nov 17
2022
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,419
+26.62%
|
-
|
|
Nov 17
2022
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,805
+4.74%
|
-
|
|
Nov 17
2022
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,774
+2.74%
|
-
|
|
Nov 17
2022
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,419
+3.38%
|
-
|
|
Nov 17
2022
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,774
+4.78%
|
-
|
|
Sep 02
2022
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
1,320
-1.18%
|
$22,440
$17.01 P/Share
|
|
Aug 17
2022
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
1,797
-1.58%
|
$25,158
$14.96 P/Share
|
|
Aug 17
2022
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,805
+4.85%
|
-
|
|
Aug 17
2022
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
725
-1.08%
|
$10,150
$14.96 P/Share
|
|
Aug 17
2022
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,418
+3.46%
|
-
|
|
Aug 17
2022
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,145
-3.3%
|
$16,030
$14.96 P/Share
|
|
Aug 17
2022
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,773
+4.86%
|
-
|
|
Aug 17
2022
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
532
-0.86%
|
$7,448
$14.96 P/Share
|
|
Aug 17
2022
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,773
+2.79%
|
-
|
|
Aug 17
2022
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
725
-29.98%
|
$10,150
$14.96 P/Share
|
|
Aug 17
2022
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,418
+50.0%
|
-
|
|
Jul 02
2022
|
Thomas Andrew Crockett CEO |
SELL
Bona fide gift
|
Direct |
6,500
-5.48%
|
-
|
|
Mar 09
2022
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
10,000
-8.02%
|
$170,000
$17.07 P/Share
|
|
Jan 07
2022
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
57,657
+38.44%
|
$403,599
$7.64 P/Share
|